CStone plans Phase I CS5007-101 trial in advanced solid tumors after IND filing

PUBT·04/20/2026 00:01:05

Listen to the news

CStone highlighted preclinical results for three antibody-drug conjugate candidates at AACR 2026, including lead program CS5007 targeting EGFR and HER3.
Data presented showed CS5007 produced broad anti-tumor activity in laboratory and animal models, including activity in models designed to reflect treatment resistance.
CStone outlined plans to file an IND for CS5007 in 1H 2026, setting up a Phase I monotherapy dose-escalation and expansion study in advanced solid tumors.
Planned CS5007-101 trial targets enrollment of about 70 adult patients with advanced solid tumors.
Separate IND filings were slated for CS5006 and CS5008 in 2H 2026, positioning multiple new oncology assets for clinical entry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12111236), on April 20, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English